The performance of companies tied to Sildenafil's legacy presents a intricate investment scenario . While the initial surge generated substantial returns , generic alternatives have significantly impacted market share . Investing in related pharmaceutical businesses now requires a thorough assessment of intellectual property safeguards, evolving he